Angiopoietin like protein 3 (Angptl3), fatty acid binding protein 4 (FABP4) and homeostasis model assessment of insulin resistance (HOMA-IR) among Indonesian obese non diabetic males
Aim To reveal the correlation between Angptl3, FABP4 and HOMA-IR among Indonesian obese non diabetic males.
Methods This is a cross sectional study with 133 obese non diabetic males volunteers (characterized by waist circumference > 90 cm; fasting blood glucose < 126 mg/dL; and no diabetic specific symptoms) age between 30-60 years which was done in Jakarta, Indonesia. We measured biochemical markers such as Angptl3, FABP4, FFA, fasting insulin and fasting glucose. We also measured weight, height, waist circumference (WC), systolic blood pressure (SBP) and diastolic blood pressure (DBP). Correlation between each marker was measured using Pearson and Spearman's analysis.
Results Pearson and Spearman's correlation analysis showed significant positive correlation between Angptl3 and FABP4 (r = 0.319; P = 0.000), Angptl3 and FFA (r = 0.171; r = 0.049), FABP4 and HOMA-IR (r = 0.202; P = 0.019), FFA and FABP4 (r = 0.506; P = 0.000), WC and HOMA-IR (r = 0.323; P = 0.000), WC and FABP4 (r = 0.387; P = 0.000), Body Mass Index (BMI) and HOMA-IR (r = 0.270; P = 0.002), BMI and FABP4 (r = 0.362; P = 0.000).
Conclusion This study showed positive significant correlations between Angptl3-FABP4, Angptl3-FFA, FFA-FABP4 and FABP4-HOMA-IR. We suggest that Angptl3 can activate lipolysis in adipose tissue (through its correlation with FABP4), and Angptl3 concentration is related to insulin resistance risk among Indonesian obese non diabetic males. (Med J Indones 2010;19:185-90)
Asia Pacific Cohort Studies Collaboration. The burden of overweight and obesity in the Asia-Pacific region. Obes Rev. 2007; 8: 191-6
Boden G. Free fatty acid as target for therapy. Curr Opin Endocrinol Diabetes. 2004; 11: 258-63
Furuhashi M, Hotamisligil GS. Fatty acid binding proteins : role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov. 2008; 7: 489-503
Boord JB, Fazio S, Linton MF. Cytoplasmic fatty acid-binding protein: emerging roles in metabolism and atherosclerosis. Curr Opin Lipidol. 2002; 13: 141-7
Oike Y, Akao M, Kubota Y, Suda T. Angiopoietin-like proteins: potencial new targets for metabolic syndrome therapy. Trends Mol Med. 2005; 11: 473-9
Hato T, Tabata M, Oike Y. The role of angiopoietin-like proteins in angiogenesis and metabolism. Trends Cardiovasc Med. 2008; 18: 6–14
Shimamura M, Matsuda M, Kobayashi S, Ando Y, Ono M, Koishi R, et al. Angiopoietin-like protein 3, a hepatic secretory factor, activates lipolysis in adipocyte. Biochem Biophys Res Commun. 2003; 301: 604-9
Shimamura M, Matsuda M, Yasumo H, Okazaki M, Fujimoto K, Kono K, et al. Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase. Arterioscler Thromb Vasc Biol. 2007; 27: 366-72
Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA-IR modeling. Diab Care. 2004; 27: 1487–95
Kraegen EW, Cooney GJ. Free fatty acids and skeletal muscle insulin resistance. Curr Opin Lipidol. 2008; 19: 235-41
Makowski L, Hotamisligil HS. Fatty acid binding proteins the evolutionary crossroads of inflammatory and metabolic responses. J Nutr. 2004; 134: 2464S–8S
Xu A, Tso AWK, Cheung BMY, Wang Y, Wat NMS, Fong CHY, et al. Circulating adipocyte–fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation. 2007; 115: 1537-43
Furuhashi M, Hotamisligil GS. Fatty acid-binding proteins : role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov. 2008; 7: 489-503
Jenkins-Kruchten AE, Bennaars-Eiden A, Ross JR, Shen WJ, Kraemer FB, Bernlohr DA. Fatty-acid binding protein-hormone sensitive lipase interaction. J Biol Chem. 2003; 278: 47636-43
Jun Shen W, Liang Y, Hong R, Patel S, Natu V, Sridhar K, et al. Characterization of the functional interaction of adipocyte lipid-binding protein with hormone-sensitive lipase. J Biol Chem. 2001; 276: 49443–8
Copyright (c) 2010 Yani Lina, Gatot S. Lawrence, Andi Wijaya, Suryani Asâad
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with Medical Journal of Indonesia agree to the following terms:
- Authors retain copyright and grant Medical Journal of Indonesia right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License that allows others to remix, adapt, build upon the work non-commercially with an acknowledgment of the work’s authorship and initial publication in Medical Journal of Indonesia.
- Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Medical Journal of Indonesia.